Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest CYP2D6 Stories

2014-03-20 08:30:39

Data shows that dextromethorphan exerts antidepressant-like actions mediated at least in part through sigma-1 receptors ALISO VIEJO, Calif., March 20, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the publication of data showing that dextromethorphan has antidepressant-like effects in vivo. The study, published in PLOS ONE, an international, peer-reviewed, open-access medical journal, examined the antidepressant activity of dextromethorphan and the...

2013-10-02 14:08:11

Findings likely to improve how patients are prescribed one in four clinically used drugs The discovery of genetic differences affecting up to a third of the population could take the guesswork out of prescribing the correct dose of 25 percent of drugs currently on the market, researchers say. The scientists found two genetic variants that alter the activity level of an enzyme responsible for processing, or metabolizing, drugs ranging from the painkiller codeine to the breast cancer drug...

2013-09-23 16:24:12

New Cytochrome P450 2C19 Assay Helps Physicians Optimize Individual Patient Care AUSTIN, Texas, Sept. 23, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a comprehensive genotyping assay, xTAG® CYP2C19 Kit. This new test enables a personalized approach to aid physicians in determining patient treatment plans based on certain genetic variants of the P450 2C19 gene. (Logo:...

2013-07-15 16:23:50

Luminex Submits xTAG® CYP2C19 Kit to FDA for Review AUSTIN, Texas, July 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a new version of xTAG CYP2D6 Kit. Additionally the company has submitted xTAG 2C19 Kit to FDA for review. Luminex is advancing its pharmacogenetic initiative for improved patient care. (Photo: http://photos.prnewswire.com/prnh/20130715/DA47259) (Logo:...

2012-06-11 11:35:35

French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients. Dr Laurent Varin, an anesthesiologist at the Caen Teaching Hospital (Caen, France), presented the findings to the European Anaesthesiology...

2012-03-07 11:00:53

Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer. Both studies found that CYP2D6 genotypes that were indicative of reduced activity of enzymes that metabolize tamoxifen did not predict...

2010-11-24 07:51:50

(Ivanhoe Newswire) -- Cough medicine could be used as way of predicting how well individual patients metabolize tamoxifen used in the treatment of their breast cancer, according to a new study. The findings suggest that it could be possible to use cough syrup as a probe, which would enable doctors to identify patients with altered metabolism and use this information to improve individual treatment, making it more effective and reducing the chances of side-effects.Tamoxifen, which is widely...

2010-11-19 12:30:18

Finding could help doctors to improve individual treatments Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Friday). The findings suggest that it could be possible to use cough suppressant syrup as a probe, which would enable doctors to identify patients with...

2010-11-17 08:45:00

AUSTIN, Texas, Nov. 17, 2010 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that it has commercially launched its first pharmacogenetic test, the xTAG® CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The new test enables a personalized medicine approach to help physicians manage patients for whom they may prescribe certain drugs that are metabolized by the enzyme cytochrome P450 2D6....

2010-03-24 14:37:48

Barcelona, Spain -- Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors (SSRIs), prescribed drugs that inhibit the effect of an important enzyme. Now researchers have developed a strategy for overcoming this problem, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today (Wednesday). Mr. Sean...